| 000 | 01215 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250517201911.0 | ||
| 264 | 0 | _c20180326 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1744-7658 | ||
| 024 | 7 |
_a10.1080/13543784.2018.1442433 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLabetoulle, Remi | |
| 245 | 0 | 0 |
_aFilgotinib for the treatment of Crohn's disease. _h[electronic resource] |
| 260 |
_bExpert opinion on investigational drugs _cMar 2018 |
||
| 300 |
_a295-300 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aGastrointestinal Agents _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJanus Kinase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aPyridines _xadverse effects |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 |
_aTriazoles _xadverse effects |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aPaul, Stephane | |
| 700 | 1 | _aRoblin, Xavier | |
| 773 | 0 |
_tExpert opinion on investigational drugs _gvol. 27 _gno. 3 _gp. 295-300 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/13543784.2018.1442433 _zAvailable from publisher's website |
| 999 |
_c28091109 _d28091109 |
||